Compound in green tea found to block rheumatoid arthritis
gadost0, pixabay, CC0
Rheumatoid arthritis is a debilitating autoimmune disorder that mostly affects the small joints of the hands and feet. It causes painful swelling that progresses into cartilage damage, bone erosion and joint deformity.
"Existing drugs for rheumatoid arthritis are expensive, immunosuppressive and sometimes unsuitable for long-term use," said Salah-uddin Ahmed, the lead WSU researcher on the project.
His team evaluated a phytochemical called epigallocatechin-3-gallate (EGCG), which is a molecule with anti-inflammatory properties found in green tea. Their study suggests that EGCG has high potential as a treatment for rheumatoid arthritis because of how effectively the molecule blocks the effects of the disease without blocking other cellular functions.
"This study has opened the field of research into using EGCG for targeting TAK1 - an important signaling protein - through which proinflammatory cytokines transmit their signals to cause inflammation and tissue destruction in rheumatoid arthritis," said Ahmed.
The researchers confirmed their findings in a pre-clinical animal model of human rheumatoid arthritis, where they observed that ankle swelling in animals given EGCG in a 10-day treatment plan was markedly reduced.
Ahmed has focused his research on studies related to rheumatoid arthritis for the last 15 years.
The WSU team, which includes researchers Anil Singh and Sadiq Umar, has been studying rheumatoid arthritis and other inflammatory diseases at the WSU College of Pharmacy in Spokane since 2014. They joined with researchers from the National Institute of Pharmaceutical Education and Research in Hajipur, India, for this project.
Original publication
Anil K. Singh, Sadiq Umar, Sharayah Riegsecker, Mukesh Chourasia and Salahuddin Ahmed; "Regulation of Transforming Growth Factor β–Activated Kinase Activation by Epigallocatechin-3-Gallate in Rheumatoid Arthritis Synovial Fibroblasts: Suppression of K63-Linked Autoubiquitination of Tumor Necrosis Factor Receptor–Associated Factor 6"; Arthritis and Rheumatology; 2016
Original publication
Anil K. Singh, Sadiq Umar, Sharayah Riegsecker, Mukesh Chourasia and Salahuddin Ahmed; "Regulation of Transforming Growth Factor β–Activated Kinase Activation by Epigallocatechin-3-Gallate in Rheumatoid Arthritis Synovial Fibroblasts: Suppression of K63-Linked Autoubiquitination of Tumor Necrosis Factor Receptor–Associated Factor 6"; Arthritis and Rheumatology; 2016
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.